ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application

Introduction: There exist controversies on recurrence and aggressiveness after use of first-line bevacizumab (BEV) which has been approved in Japan and proven to be beneficial. Therefore, we analyzed the clinical impact of BEV approval by investigating the overall clinical course and glioblastoma (G...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neurooncol Adv
Huvudupphovsmän: Funakoshi, Yusuke, Hata, Nobuhiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Mizoguchi, Masahiro
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Supplement Abstracts
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7699102/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.032
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk